Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Phase 2

Terminated

Conditions: Diabetes Mellitus and Heart Failure

Interventions: Drug: LIK066
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2019-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT03152552

Locations: 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: brinzolamide 1%/brimonidine 0.2% fixed combination
Drug: Placebo
Drug: travoprost 0.004% ophthalmic solution

First Posted Date: 2017-05-12

Last Posted Date: 2019-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03150160

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Phase 2

Terminated

Conditions: Circadian Rhythm Disorders

Interventions: Drug: LML134
Drug: Placebo

First Posted Date: 2017-05-04

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03141086

Locations: 🇺🇸
Novartis Investigative Site, Cincinnati, Ohio, United States

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo Comparator

First Posted Date: 2017-05-03

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT03138811

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: NVA237 (glycopyrronium bromide)
Drug: Placebo

First Posted Date: 2017-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT03137784

Locations: 🇱🇹
Novartis Investigative Site, Klaipeda, Lithuania

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Phase 3

Completed

Conditions: Spondyloarthritis

Interventions: Biological: AIN457
Drug: AIN457 Placebo

First Posted Date: 2017-05-02

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 383

Registration Number: NCT03136861

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Phase 2

Completed

Conditions: Renal Impairment

Interventions: Drug: LIK066

First Posted Date: 2017-04-27

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT03131479

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimers Disease

Interventions: Drug: CNP520 50mg
Drug: CNP520 15mg
Other: Matching placebo

First Posted Date: 2017-04-27

Last Posted Date: 2021-08-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1145

Registration Number: NCT03131453

Locations: 🇺🇸
Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States
🇺🇸
Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 33 locations

Phase III B in Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2017-04-21

Last Posted Date: 2021-07-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 69

Registration Number: NCT03123939

Locations: 🇪🇸
Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
KRAS G12-mutant NSCLC
Esophageal Squamous Cell Cancer (SCC)
Head/Neck SCC
Melanoma
Advanced Gastrointestinal Stromal Tumors (GIST)
Advanced NRAS/BRAFT wt Cutaneous Melanoma

Interventions: Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)

First Posted Date: 2017-04-14

Last Posted Date: 2025-05-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 227

Registration Number: NCT03114319

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloane Ketterin Cancer Ctr, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy